Search results for "Staging."

showing 10 items of 715 documents

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE…

2021

International audience; Aim Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper was to report 3-year oncological outcomes, representing the secondary endpoints of the PRODIGE 22 trial. Method PRODIGE 22 was a randomized multicentre phase II trial in high-risk T3, T4 and/or N2 CC patients on CT scan. Patients were randomized between 6 months of adjuvant FOLFOX (upfront surgery) or perioperative FOLFOX (four cycles before surgery and eight cycles after; FOLFOX perioperative). In wild-type RAS patients, a third arm testing perioperative FOLFOX-cetuximab was added. The pri…

Oncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancer[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulationLeucovorinsurvival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationNeoplasm StagingColectomyeducation.field_of_studybusiness.industryHazard ratioGastroenterologyPerioperativecolectomyPrognosisInterim analysismedicine.diseaseNeoadjuvant Therapydigestive system diseasescolon cancerChemotherapy Adjuvant030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFluorouracilNeoplasm Recurrence Localbusinessneoadjuvant chemotherapyFollow-Up Studiesmedicine.drugColorectal Disease
researchProduct

Impact of molecular and histological subtype of breast cancer on 18FDG-PET/CT imaging: Knowledge gained from recent studies

2016

International audience; Over the past few years, several studies have focused attention on the impact of breast cancer (BC) histological subtype or BC phenotype, as defined by hormone receptors (HR) and HER2 status, on the results of FDG-PET/CT at staging, or during neoadjuvant chemotherapy (NAC). At staging, sclerotic bone metastases from invasive lobular carcinoma (ILC) demonstrated low or no FDG uptake in comparison to metastases from invasive ductal carcinoma (IDC). The CT component of PET/CT imaging should be carefully analyzed in the staging of ILC. In patients with triple negative or HER2-positive tumors, the proportion of extraskeletal metastases is high; this must be taken into acc…

Oncologymedicine.medical_specialtyPathologyStagingPET/CTmedicine.medical_treatmentBiophysicsEstrogen receptorER-positive breast cancerNeoadjuvant chemotherapy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerTriple-negative breast cancerResponse assessmentInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineRadiology Nuclear Medicine and imagingskin and connective tissue diseasesHER2-positive breast cancerTriple-negative breast cancerChemotherapyPET-CTPathological complete responseRadiological and Ultrasound Technologybusiness.industrymedicine.disease18fdg pet ctPrognosis3. Good healthHormone receptor030220 oncology & carcinogenesisInvasive lobular carcinoma(18)FDGbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Role of robotic surgery in ovarian malignancy

2017

As part of minimally invasive surgery, robotic-assisted approach is becoming increasingly popular in gynecologic oncology. It has been shown to be effective and feasible for staging and treating endometrial and cervical cancer, but its role in the context of primary and recurrent ovarian cancers is presently debated. Scanty data are available in the literature, and the level of evidence supporting its use in ovarian cancer is quite low. However, from a retrospective case-control series, robotic surgery seems to be safe and feasible for early-stage ovarian cancer. Its use in treating patients with advanced-stage or relapsed ovarian cancer is still highly controversial, suggesting the choice …

Oncologymedicine.medical_specialtyPopulationContext (language use)robotic surgery ovarian cancerGynecologic oncologygynecologic oncology03 medical and health sciencesGynecologic Surgical Procedures0302 clinical medicineRobotic Surgical ProceduresInternal medicinerobotic surgerymedicineHumansRobotic surgeryeducationOvarian malignancygynecologic oncology; minimally invasive surgery; ovarian cancer; robotic surgery; Obstetrics and Gynecologyminimally invasive surgeryNeoplasm StagingRetrospective StudiesOvarian NeoplasmsCervical cancereducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryGeneral surgeryObstetrics and GynecologyGeneral MedicineEvidence-based medicinemedicine.diseasegynecologic oncology; minimally invasive surgery; ovarian cancer; robotic surgery; Case-Control Studies; Female; Gynecologic Surgical Procedures; Humans; Neoplasm Recurrence Local; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Robotic Surgical Procedures; Treatment OutcomeTreatment Outcomeovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIACase-Control Studies030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessOvarian cancer
researchProduct

Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status

2015

International audience; We aim to describe trends in net survival (NS) and to assess the prognostic factors among women with de novo metastatic breast cancer (MBC) according to human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status. Data on women suffering from de novo MBC and diagnosed from 1998 to 2009 were provided by the Côte-d'Or breast cancer registry. NS was described using the Pohar Perme estimator and prognostic factors were investigated in a generalised linear model. We identified 232 patients (mean age = 64.7). Median NS was 29.2 months, 1- and 5-year NS were 76% and 26% respectively. The survival trend in patients with HER2-positive tumours who did not …

Oncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsTriple Negative Breast NeoplasmsLower riskBreast cancerTrastuzumabInternal medicinemedicineHumansNeoplasm Metastasisskin and connective tissue diseasesAgedNeoplasm StagingGynecologyregisterbusiness.industryCarcinoma Ductal BreastAge FactorsAbsolute risk reductionhormone receptorsCancerTriple Negative Breast NeoplasmsMiddle AgedTrastuzumabHER2 receptorsPrognosismedicine.diseaseMetastatic breast cancerConfidence interval3. Good healthpopulation-basedCarcinoma LobularReceptors EstrogenOncologyLinear ModelsFemalemetastatic breast cancernet survivalReceptors Progesteronebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Vulvar cancer: a review for dermatologists.

2015

Vulvar malignancies are important tumors of the female reproductive system. They represent a serious health issue with an incidence between 2 and 7 per 100,000 and year. We provide a review about most important cancer entities, i.e., melanoma, squamous cell carcinoma, basal cell carcinoma, neuroendocrine cancer, and skin adnexal malignancies. Squamous cell carcinoma is the most common vulvar malignancy that can develop from vulvar intraepithelial neoplasia or de novo. Basal cell carcinoma represents only 2 % of all vulvar cancers. Melanoma of the vulva exists in two major types—superficial spreading and acral lentiginous. A special feature is the occurrence of multiple vulvar melanomas. Of …

Oncologymedicine.medical_specialtySkin NeoplasmsMalignancyVulvaVulvaDiagnosis DifferentialVulva · Squamous cell carcinoma · Basal cell carcinoma · Melanoma · Paget’s disease · Adnexal carcinomasInternal medicineCarcinomamedicineSettore MED/35 - Malattie Cutanee E VenereeHumansBasal cell carcinomaMelanomaNeoplasm StagingSkinintegumentary systemVulvar Neoplasmsurogenital systembusiness.industryMelanomaCancerGeneral MedicineVulvar cancermedicine.diseaseVulvar intraepithelial neoplasiaPrognosisDermatologyfemale genital diseases and pregnancy complicationsNeuroendocrine Tumorsmedicine.anatomical_structurePaget Disease ExtramammaryCarcinoma Basal CellCarcinoma Squamous CellFemaleNeoplasms Adnexal and Skin AppendagebusinessCarcinoma in SituWiener medizinische Wochenschrift (1946)
researchProduct

(Neo)adjuvant Strategies of Advanced Gastric Carcinoma: Time for a Change?

2005

Despite surgical R0 resections, patients with gastric cancer stage UICC II–III have a high risk of recurrence and metachronic metastases. Preliminary evidence exists that adjuvant chemotherapy or neoadjuvant chemo(radio)therapy protocols may improve the prognosis of these patients undergoing surgery of gastric cancer with curative intention. As for palliative regimens, 5-fluorouracil and cisplatin are integral components of such (neo)adjuvant strategies. Upcoming cytostatic agents, i.e. irinotecan, docetaxel, oxaliplatin, and oral fluoropyridines are currently under investigation in new multimodality treatment regimens and may further increase R0 resection rates and may prolong disease-free…

Oncologymedicine.medical_specialtymedicine.medical_treatmentGastric carcinomaStomach NeoplasmsInternal medicinemedicineHumansNeoplasm StagingCisplatinChemotherapybusiness.industryCarcinomaGastroenterologyCancerGeneral Medicinemedicine.diseaseNeoadjuvant Therapydigestive system diseasesOxaliplatinIrinotecanDocetaxelPractice Guidelines as TopicbusinessAdjuvantmedicine.drugDigestive Diseases
researchProduct

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

2006

Item does not contain fulltext BACKGROUND: Loss of TP53 function through gene mutation is a critical event in the development and progression of many tumour types including colorectal cancer (CRC). In vitro studies have found considerable heterogeneity amongst different TP53 mutants in terms of their transactivating abilities. The aim of this work was to evaluate whether TP53 mutations classified as functionally inactive (< or=20% of wildtype transactivation ability) had different prognostic and predictive values in CRC compared with mutations that retained significant activity. MATERIALS AND METHODS: TP53 mutations within a large, international database of CRC (n = 3583) were classified ac…

Oncologyp53MaleNutrition and Diseasebinding domainsLymphovascular invasionColorectal cancerDNA Mutational AnalysisAetiology screening and detection [ONCOL 5]Gene mutationmedicine.disease_causeTransactivationVoeding en ZiekteAntineoplastic Combined Chemotherapy ProtocolsDeterminants in Health and Disease [EBP 1]transcriptional activityMutationHematologyExonsMiddle AgedSurvival RateOncologyAdenocarcinomaFemaleColorectal Neoplasmsmedicine.medical_specialtyAdenocarcinomachemotherapy colorectal cancer mutation prognosis TP53 transactivational abilityMolecular epidemiology [NCEBP 1]Breast cancerTranslational research [ONCOL 3]Interventional oncology [UMCN 1.5]Internal medicinemedicineHumansNeoplasm InvasivenessSurvival rateneoplasmsbreast-cancerVLAGAgedNeoplasm StagingHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryInternational Agenciesmedicine.diseaseImmunologyMutationTumor Suppressor Protein p53businessFollow-Up Studies
researchProduct

Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer

2005

Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role …

Oncologystage IIIA-N2medicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.medical_treatmentDocetaxelNSCLCDeoxycytidinemolecular markers analysisCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineStage (cooking)Lung cancerNeoplasm StagingCisplatinChemotherapybusiness.industryInduction chemotherapyHematologymedicine.diseaseearly stageGemcitabineRadiation therapyneoadjuvant radiotherapyOncologyTolerabilityDocetaxelChemotherapy AdjuvantRadiotherapy AdjuvantTaxoidsCisplatinbusinessmedicine.drugneoadjuvant chemotherapy
researchProduct

Bipolar disorder comorbid with alcohol use disorder: focus on neurocognitive correlates

2015

Bipolar disorder (BD) and alcohol use disorders (AUDs) are usually comorbid, and both have been associated with significant neurocognitive impairment. Patients with the BD-AUD comorbidity (dual diagnosis) may have more severe neurocognitive deficits than those with a single diagnosis, but there is paucity of research in this area. To explore this hypothesis more thoroughly, we carried out a systematic literature review through January 2015. Eight studies have examined the effect of AUDs on the neurocognitive functioning of BD patients. Most studies found that BD patients with current or past history of comorbid AUDs show more severe impairments, especially in verbal memory and executive cog…

PHYSIOLOGY (MEDICAL)medicine.medical_specialtyStagingPhysiologyBipolar disorderneurocognitionAddictionReviewAlcohol use disorderComorbiditylcsh:PhysiologyAlcohol use disordersComorbiditatalcohol use disordersPhysiology (medical)mental disordersmedicineManic-depressive illnessBipolar disorderPsychiatryPHYSIOLOGYNeurocognitionbipolar disorderTrastorn bipolarlcsh:QP1-981business.industryCognitionsystems biologystagingmedicine.diseaseComorbidityAlcoholismcomorbiditySystems Biology.Systematic reviewAlcoholismeDual diagnosisaddictionVerbal memorybusinessSystems biologyNeurocognitive
researchProduct

Diagnosis of oral squamous cell carcinoma and its precursor lesions

2007

Improvement of survival rate and quality of life after treatment of oral squamous cell carcinoma as well as cost reduction requires reliable early diagnosis of the tumor and its precursor lesions. Four different screening methods are primarily employed: toluidine blue staining (visually detected lesions: sensitivity 70-100%, specificity 25-67%), photodynamic diagnosis (sensitivity 94-99%, specificity 60-89%), autofluorescence (no data published so far) and modern oral cytology (sensitivity 80%,specificity 95-100%). Additional analytic procedures such automated image analysis, DNA image cytometry and immunocytochemistry can be used to enhance the low sensitivity of conventional oral cytology…

Pathologymedicine.medical_specialtyBiopsyDermatologyFluorescenceCytologyBiopsyImage Processing Computer-AssistedCarcinomaHumansMedicineTolonium ChlorideSurvival rateDNA Image CytometryNeoplasm StagingMouth neoplasmmedicine.diagnostic_testbusiness.industryMouth MucosaGold standard (test)Prognosismedicine.diseasestomatognathic diseasesAutofluorescenceCarcinoma Squamous CellMouth NeoplasmsbusinessPrecancerous ConditionsJDDG
researchProduct